These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 9249034)

  • 1. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
    Wang J; Mazar A; Quan N; Schneider A; Henkin J
    Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
    Husain SS
    Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
    Wilhelm S; Wilhelm O; Schmitt M; Graeff H
    Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
    Longstaff C; Merton RE; Fabregas P; Felez J
    Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
    Baker MS; Liang XM; Doe WF
    Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N; List K; Andreasen PA; Danø K
    Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N; Danø K
    FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V; Whawell SA; Werner F; Deadman JJ
    Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.